Słota Łukasz, Sędek Łukasz, Kulis Jan, Perkowski Bartosz, Malinowska Iwona, Zawitkowska Joanna, Kazanowska Bernarda, Derwich Katarzyna, Niedźwiecki Maciej, Mizia-Malarz Agnieszka, Muszyńska-Rosłan Katarzyna, Kołtan Andrzej, Karolczyk Grażyna, Machnik Katarzyna, Urasiński Tomasz, Lejman Monika, Badowska Wanda, Młynarski Wojciech, Kowalczyk Jerzy, Szczepański Tomasz
Department of Pediatric Hematology and Oncology, Medical University of Silesia, Katowice, Poland.
Department of Microbiology and Immunology, Medical University of Silesia, Katowice, Poland.
Cent Eur J Immunol. 2022;47(1):84-91. doi: 10.5114/ceji.2022.114530. Epub 2022 Mar 17.
Flow cytometry (FCM) is a precise and well-established tool to assess the minimal residual disease (MRD) level in childhood acute lymphoblastic leukemia (ALL). It is crucial to distinguish leukemic cells from their normal counterparts; thus new markers should be evaluated, to increase the accuracy of the analysis. The expression of CD73 on blast cells was measured and compared at the day of diagnosis and at days 15 and 33 of treatment. To determine antigen expression levels, a normalized scale based on median fluorescence intensity (nMFI) was used. The study group consisted of 188 patients from the Polish Pediatric Leukemia and Lymphoma Study Group. From 177 patients with positive MRD at day 15 of treatment, in 147 (83.1%) cases an increase of CD73 expression was observed (mean increase of +17 nMFI units). In addition, an increase of CD73 expression was noted in 26 of 31 (83.9%) patients at day 33 of treatment. In turn, a decrease of CD73 expression was observed only in 13/177 (7.3%) and 1/31 (3.2%) cases at days 15 and 33 of treatment, respectively. In 17 (9.6%) patients no change in expression of CD73 between diagnosis and day 15 of treatment was observed. In the great majority of cases the expression of CD73 is not only stable but increases during the early stages of treatment, which makes it a very useful marker to be used for MRD monitoring in childhood B-cell precursor (BCP)-ALL patients.
流式细胞术（FCM）是一种精确且成熟的工具，用于评估儿童急性淋巴细胞白血病（ALL）中的微小残留病（MRD）水平。将白血病细胞与其正常对应细胞区分开来至关重要；因此，应评估新的标志物，以提高分析的准确性。在诊断当天以及治疗的第15天和第33天测量并比较原始细胞上CD73的表达。为了确定抗原表达水平，使用了基于中位荧光强度（nMFI）的标准化量表。研究组由来自波兰儿童白血病和淋巴瘤研究组的188名患者组成。在治疗第15天MRD呈阳性的177名患者中，有147例（83.1%）观察到CD73表达增加（平均增加+17 nMFI单位）。此外，在治疗第33天的31名患者中有26例（83.9%）观察到CD73表达增加。相反，仅在治疗第15天和第33天分别有13/177例（7.3%）和1/31例（3.2%）观察到CD73表达下降。在17例（9.6%）患者中，未观察到诊断至治疗第15天期间CD73表达有变化。在绝大多数情况下，CD73的表达不仅稳定，而且在治疗早期会增加，这使其成为用于监测儿童B细胞前体（BCP）-ALL患者MRD的非常有用的标志物。
